Literature DB >> 3342284

Types of mean residence times.

J G Wagner1.   

Abstract

Mean residence times (MRTs) have been classified into two main groups, namely system moment MRT [MRT(S,MO] and system matrix MRT [MRT(S,MA]. There are also MRTs of individual compartments [MRT(i)] such as central or plasma compartment, [MRT(P)], and tissue compartments and the MRT of an absorption site, [MRT(A)]. Much of the literature on MRTs does not clearly indicate which MRT is being discussed. MRT(S,MO) has been termed non-compartmental, but is really based on a structured model. There are really no model-independent MRTs or steady-state volumes of distribution. For the classical two-compartment open model with central compartment input, sampling and elimination MRT(S,MO) = MRT(S,MA) for a given set of microscopic rate constants. When elimination occurs from any but the central compartment then MRT(S,MO) is not equal to MRT(S,MA). For 'first-pass' drugs it is necessary to have a model where elimination occurs from a compartment different from the central and sampling compartment. Many of the methods of estimating MRTs which have been reported in the literature to date are reviewed and some generalizations are drawn. Some uses of MRTs are indicated. These uses involve both amounts of drug in the body as well as concentrations. The relationship between MRT(S,MO) and MRT(S,MA) for the Rowland two-compartment open model with peripheral compartment elimination is: MRT(S,MA)--MRT(S,MO) = 1/(k20 + k21). Thus the system matrix MRT is always larger than the system moment MRT for this linear model, which is most useful for 'first-pass' drugs. A general equation for MRT(S,MA) of all three two-compartment open models with input into either of the compartments is (lambda 1 + lambda 2 - ki0)/lambda 1 lambda 2 where i is the compartment (i = 1 or 2) into which input occurs.

Mesh:

Substances:

Year:  1988        PMID: 3342284     DOI: 10.1002/bod.2510090106

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  8 in total

1.  The relevance of residence time theory to pharmacokinetics.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Systems dynamics in clinical pharmacokinetics. An introduction.

Authors:  J M van Rossum; J E de Bie
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

Review 3.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

4.  Stepwise determination of multicompartment disposition and absorption parameters from extravascular concentration-time data. Application to mesoridazine, flurbiprofen, flunarizine, labetalol, and diazepam.

Authors:  J G Wagner; D A Ganes; K K Midha; I Gonzalez-Younes; J C Sackellares; L D Olson; M B Affrime; J E Patrick
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

5.  Stereoselective disposition of flurbiprofen in uraemic patients.

Authors:  M P Knadler; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

6.  Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes.

Authors:  S Soback; M Gips; M Bialer; A Bor
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

7.  Investigations into the route of uptake and pharmacokinetics of intraperitoneally-administered monoclonal antibodies: I. Transdiaphragmatic blockade of the terminal lymphatics in the rat.

Authors:  J S Barrett; R L Wahl; J G Wagner; R Brown; S J Fisher
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.

Authors:  A C Rudy; N L Figueroa; S D Hall; D C Brater
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.